Robert Gross, MD, MSCE
Professor of Medicine
Attending Physician, Infectious Diseases, Corporal Michael J. Crescenz Veterans Affairs Medical Center
Member, Abramson Cancer Center, University of Pennsylvania, Perelman School of Medicine
Senior Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Perelman School of Medicine
Senior Fellow, Leonard Davis Institute, University of Pennsylvania, Perelman School of Medicine
Co-Director, Clinical Core, Penn Center for AIDS Research (CFAR) Perelman School of Medicine
Co-Director, Clinical Assessment Core, Penn Mental Health in AIDS Research Center
Senior Fellow , Center for Public Health Initiatives (CPHI), Perelman School of Medicine
Co-Director , Penn Center for AIDS Research, Perelman School of Medicine
Director, International Core, Penn Center for AIDS Research, International Core
Center for Global Health Scholar, University of Pennsylvania Perelman School of Medicine
Department: Medicine
Contact information
804 Blockley Hall
Center for Clinical Epidemiology and Biostatistics
University of Pennsylvania, Perelman School of Medicine
423 Guardian Drive
Philadelphia, PA 19104-6021
Center for Clinical Epidemiology and Biostatistics
University of Pennsylvania, Perelman School of Medicine
423 Guardian Drive
Philadelphia, PA 19104-6021
Office: 215-898-2437
Fax: 215-573-5315
Fax: 215-573-5315
Publications
Links
Search PubMed for articles
Center for Clinical Epidemiology and Biostatistics faculty webpage.
Search PubMed for articles
Center for Clinical Epidemiology and Biostatistics faculty webpage.
Education:
BA (Italian)
Cornell University , 1986.
MD
Cornell University, 1991.
MSCE (Pharmacoepidemiology)
University of Pennsylvania, 2000.
Permanent linkBA (Italian)
Cornell University , 1986.
MD
Cornell University, 1991.
MSCE (Pharmacoepidemiology)
University of Pennsylvania, 2000.
Description of Research Expertise
HIV clinical epidemiology; outcomes of HIV treatment; adherence to therapy including development of methods to measure adherenceDescription of Clinical Expertise
HIV; infectious diseasesSelected Publications
Pickel J, Fiks AG, Karavite D, Maleki P, Beidas RS, Dowshen N, Petsis D, Gross R, Wood S : Provider perspectives on clinical decision support to improve HIV prevention in pediatric primary care: A multiple methods study Implementation Science Communications 2023 (in press).Tsima BM, Opondo P, Mosepele M, Mautle E, Bilker WB, Gross R: Prevalence of the metabolic syndrome and associated factors among inpatients with severe mental illness in Botswana: a cross-sectional study. BMC Cardiovascular Disorders 2022 (in press).
Martei YM, Narasimhamurthy M, Setlhako DI, Ayane G, Ralefala T, Chiyapo S, Gross R, Shulman LN, Grover S, DeMichele A : Relative Dose Intensity and Pathologic Response Rates in Breast Cancer Patients with and without HIV Who Received Neoadjuvant Chemotherapy JCO Global Oncology 2022 (in press).
Bien-Gund CH, Shaw PA, Agnew-Brune C, Baugher A, Brady KA,* Gross R* for the NHBS Study Group *equal work by authors : HIV self-testing and risk behaviors among men who have sex with men in 23 US cities, 2017. JAMA Network Open 2022 (in press).
Motlokwa PK, Tsima BM, Martei YM, Ralefala T, Galebole F, Stephens-Shields AJ, Grover S,* Gross R* * equal contribution by authors : Disparities in Oral Cancer Stage at Presentation in a High HIV Prevalence Setting in Sub-Saharan Africa JCO Global Oncology 2022 (in press).
Avihingsanon A, Hughes MD, Salata R, Godfrey C, McCarthy C, Mugyenyi P, Hogg E, Gross R, Cardoso SW, Bukuru A, Makanga M, Badal-Faesen S, Mave V, Wangari Ndege B, Nerette Fontain S, Samaneka W, Secours R, Van Schalkwyk M, Mngqibisa R, Mohapi L, Valencia J, Sugandhavesa P, Montalban E, Munyanga C, Chagomerana M, Santos BR, Kumarasamy N, Kanyama C, Schooley RT, Mellors JW, Wallis CL, Collier AC, Grinsztejn B for the A5288 Study team: Third-line antiretroviral therapy including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR) is well tolerated and achieves durable virologic suppression over 144+ weeks in resource limited settings: ACTG A5288 strategy trial. Journal of the International AIDS Society 2022 (in press).
Salata RA, Grinsztejn B, Ritz J, Collier AC, Hogg E, Gross R, Godfrey C, Kumarasamy N, Kanyama C, Mellors JW, Wallis CL, Hughes MD for the ACTG A5288 Study Team : Predictors of Virologic Outcome Among People Living with HIV Who Continue A Protease Inhibitor-based Antiretroviral Regimen Following Virologic Failure With No or Limited Resistance AIDS Research and Therapy 2022 (in press).
Cioe PA, Schnoll R, Hoeppner BB, Gross R, Hitsman BL, Leone FT, Ashare R, Vilardaga R, Tashima K, Pinkston M, Kahler CW: The Impact of the COVID-19 Pandemic on Stress, Isolation, Smoking Behaviors, and Motivation to Quit in People with HIV who Smoke. AIDS and Behavior 2022 (in press).
Mannathoko N, Mosepele M, Gross R, Smith R, Alby K, Glaser L,Richard-Greenblatt M, Sharma A,Jaskowiak-Barr A, Cressman L, Sewawa K, Cowden L, Reesey E, Otukile D, Paganotti G, Mokomane M, Lautenbach E : Colonization with Extended-Spectrum Cephalosporin-Resistant Enterobacterales (ESCrE) and Carbapenem-Resistant Enterobacterales (CRE) in Healthcare and Community Settings in Botswana: An Antibiotic Resistance in Communities and Hospitals (ARCH) Study International Journal of Infectious Diseases 2022 (in press).
Arens Y, Bilker WB, Han X, Plankey M, Ware D, Friedman MR, D’Souza G, Stosor V, Shoptaw S, Schnoll RA, Tyndale RF, Ashare R*, Gross R* *equal contribution by authors: HIV Infection Does Not Explain Higher Nicotine Metabolism in People Living with HIV. JAIDS 2022 (in press).